Company news

Revelation Biosciences, Inc. news in 2021

Revelation Biosciences, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Revelation Biosciences Inc. Appoints Joseph A. Bellanti, M.D. to Scientific Advisory Board

December 5, 2021

Revelation Biosciences Inc. Announces Initiation of a Phase 2b Study to Assess Efficacy of Intranasal REVTx-99 for The Prevention of H3N2 Influenza

November 30, 2021

Revelation Biosciences Inc. Announces Creation and Appointments to Scientific Advisory Board

November 28, 2021

Revelation Biosciences Inc. Announces Initiation of a Phase 1b Clinical Study of REVTx-99 for the Experimental Treatment of Allergic Rhinitis and Chronic Nasal Congestion

November 14, 2021

Revelation Biosciences Inc. Receives Approval to Begin a Phase 1b Clinical Study of REVTx-99 as an Experimental Treatment for Allergic Rhinitis and Chronic Nasal Congestion

October 3, 2021

Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections

September 27, 2021

Decks in 2021